Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2010

View Archived Issues

EVX-001688 improves spatial memory in young and aged rats

Phase Ia trial demonstrates safety of SGN-70 in healthy subjects

GRN-529 has antidepressant, anxiolytic and analgesic effects in vivo

Boehringer Ingelheim describes novel mTOR inhibitors

FDA clears Advanced Cell Technology's phase I/II RPE trial

NeuroSearch claims new activators of voltage-gated K(V)7.2/3 potassium channel

SkyePharma advances two phase III trials of asthma candidate Flutiform in Japan

BMS-582949 shows promise to treat rheumatoid arthritis

LCZ-696 is well tolerated by patients with chronic stable heart failure in phase II trial

First-in-human data disclosed on dual PI3K/mTOR inhibitors PF-05212384 and PF-04691502

FG-4592 is safe and increases hemoglobin levels in CKD-related anemia

Roche to develop diagnostic tests to detect EGFR mutations in lung cancer

Abbott patents new serotonin 5-HT2C receptor agonists

Pivotal phase III trial of IPX-066 in early PD meets primary endpoint

Baxter and Archemix enter into agreements covering hemophilia-related assets

GW and Otsuka Pharma begin phase III cancer pain program for Sativex

Achaogen claims novel carbacephem beta-lactam antibiotics

GlaxoSmithKline discloses new orexin receptor antagonists

CEL-SCI completes global investigator meeting on phase III Multikine trial

Gilead submits NDA to FDA for single-tablet Truvada/TMC-278 combination

Vertex Pharma submits NDA to FDA for telaprevir in hepatitis C

FDA approves testosterone replacement therapy Axiron

Grifols launches Flebogamma 10% DIF in U.S.

SIRS-Lab and Pfizer collaborate on diagnostic tests to benefit patients with sepsis

Gablofen injection approved in U.S. for severe spasticity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.